Response to Letter to the Editor Regarding the Immunogenicity of Enhanced Influenza Vaccines in Inducing Neuraminidase Inhibition Antibodies - Scorecard - MDSpire
Clinical Scorecard: Reply to Editorial Correspondence on the Immunogenicity of Advanced Influenza Vaccines and Their Role in Neuraminidase Inhibition Antibody Production
At a Glance
Category
Detail
Condition
Influenza infection prevention
Key Mechanisms
Neuraminidase inhibition (NAI) antibody response induced by influenza vaccines
Target Population
Older adults
Care Setting
Vaccination in outpatient or community settings
Key Highlights
NA content in influenza vaccines is not standardized and varies across formulations.
NA protein content alone does not predict immunogenicity or NAI antibody response.
High baseline antibody titers can reduce postvaccination antibody fold-rise due to an antibody ceiling effect.
Guideline-Based Recommendations
Diagnosis
Assess baseline NAI and hemagglutination inhibition (HAI) antibody titers to interpret vaccine response.
Management
Use multiple endpoints including seroconversion rates, geometric mean titers at baseline and postvaccination, and fold-rise to evaluate vaccine immunogenicity.
Monitoring & Follow-up
Monitor NAI antibody titers pre- and postvaccination to assess immunogenicity in older adults.
Risks
Potential misclassification of vaccine response in individuals with high baseline antibody titers.
Patient & Prescribing Data
Older adults receiving enhanced influenza vaccines including standard-dose, high-dose, recombinant, and adjuvanted formulations
Enhanced vaccines with higher NA content do not necessarily elicit higher NAI antibody responses; immunogenicity depends on multiple factors beyond NA quantity.
Clinical Best Practices
Evaluate multiple immunological endpoints rather than relying solely on seroconversion rates to assess vaccine efficacy.
Consider baseline antibody levels when interpreting postvaccination antibody responses.
Recognize the current knowledge gaps in NA immunogenicity determinants and the need for standardized NA antigen quantification methods.
Future research should focus on defining immunological correlates of protection related to anti-NA antibodies.
